Blog
New
The Promise and the Problem of Rare Disease Screening
The Promise and the Problem of Rare Disease Screening
Rita Bhui
5 Min Read
Share
The Promise and the Problem of Rare Disease Screening
Rare diseases affect over 300 million people worldwide. Individually, each condition is uncommon, but together they represent a major global health burden. Advances in genomics have made it technically possible to detect disease-causing variants early even before symptoms appear.
Cell-free DNA (cfDNA) is especially promising. It allows minimally invasive, repeatable testing from blood, making it ideal for carrier screening, early diagnosis, and population scale studies. Yet despite this promise, rare disease screening struggles to scale. The problem isn't access to DNA; it's how current assays are designed.
Why Rare Variant Detection is Fundamentally Hard
Rare disease mutations are, by definition, extremely uncommon. Many occur in fewer than 1 in 10,000 people, and some are unique to a single family. This means the true biological signal is rare to begin with.
In cfDNA, the challenge is even greater. True variants may appear at less than 0.1% frequency, mixed with large amounts of background DNA. At this level, sequencing and PCR errors can look almost identical to real signals. Finding a rare variant once is hard; finding it reliably across thousands of samples is where most approaches fail.
Why Traditional Screening Breaks at Scale
Most genetic screening follows a simple model: one sample, one test. This works for common diseases and small cohorts, but it breaks down for rare disease screening.
Rare disease panels span many genes, and detecting low-frequency variants, especially in cfDNA, requires deep sequencing. Doing this separately for every individual quickly becomes expensive.
Most importantly, rare disease screening demands confidence. A negative result must be as trustworthy as a positive one. With low signal levels and little margin for error, simply running more individual tests is not the answer.
How AlgoBio Solves This
Instead of testing samples one by one, multiple samples are combined into carefully designed pools. Each sample appears in several pools, in a unique pattern. When a real rare variant is present, it repeats across the same set of pools.
This shifts detection from chasing weak signals to recognizing consistent patterns. True variants reinforce themselves, while noise is naturally filtered out without relying on technical replicates.
Pooling also makes deep sequencing affordable. Fewer sequencing reactions are needed, costs drop, and sensitivity is preserved. As more samples are added, the number of pools grows slowly, enabling hundreds or thousands of samples to be screened together.
Most importantly, this structure builds trust. Positive calls are stronger, false signals are reduced, and no variant detected truly means no variant detected.
Conclusion
Rare diseases are common in aggregate, but rare at the molecular level. Screening them at scale requires an approach designed specifically for such rarity. By combining non-invasive cfDNA sampling with multiplex, algorithm-driven pooling and reliable decoding of low-frequency variants, AlgoBio enables rare disease screening to move from individual testing to confident, population-scale detection.
More Article
The Promise and the Problem of Rare Disease Screening
Rare diseases affect over 300 million people worldwide. Individually, each condition is uncommon, but together they represent a major global health burden. Advances in genomics have made it technically possible to detect disease-causing variants early even before symptoms appear.
Cell-free DNA (cfDNA) is especially promising. It allows minimally invasive, repeatable testing from blood, making it ideal for carrier screening, early diagnosis, and population scale studies. Yet despite this promise, rare disease screening struggles to scale. The problem isn't access to DNA; it's how current assays are designed.
Why Rare Variant Detection is Fundamentally Hard
Rare disease mutations are, by definition, extremely uncommon. Many occur in fewer than 1 in 10,000 people, and some are unique to a single family. This means the true biological signal is rare to begin with.
In cfDNA, the challenge is even greater. True variants may appear at less than 0.1% frequency, mixed with large amounts of background DNA. At this level, sequencing and PCR errors can look almost identical to real signals. Finding a rare variant once is hard; finding it reliably across thousands of samples is where most approaches fail.
Why Traditional Screening Breaks at Scale
Most genetic screening follows a simple model: one sample, one test. This works for common diseases and small cohorts, but it breaks down for rare disease screening.
Rare disease panels span many genes, and detecting low-frequency variants, especially in cfDNA, requires deep sequencing. Doing this separately for every individual quickly becomes expensive.
Most importantly, rare disease screening demands confidence. A negative result must be as trustworthy as a positive one. With low signal levels and little margin for error, simply running more individual tests is not the answer.
How AlgoBio Solves This
Instead of testing samples one by one, multiple samples are combined into carefully designed pools. Each sample appears in several pools, in a unique pattern. When a real rare variant is present, it repeats across the same set of pools.
This shifts detection from chasing weak signals to recognizing consistent patterns. True variants reinforce themselves, while noise is naturally filtered out without relying on technical replicates.
Pooling also makes deep sequencing affordable. Fewer sequencing reactions are needed, costs drop, and sensitivity is preserved. As more samples are added, the number of pools grows slowly, enabling hundreds or thousands of samples to be screened together.
Most importantly, this structure builds trust. Positive calls are stronger, false signals are reduced, and no variant detected truly means no variant detected.
Conclusion
Rare diseases are common in aggregate, but rare at the molecular level. Screening them at scale requires an approach designed specifically for such rarity. By combining non-invasive cfDNA sampling with multiplex, algorithm-driven pooling and reliable decoding of low-frequency variants, AlgoBio enables rare disease screening to move from individual testing to confident, population-scale detection.
More Article
The Promise and the Problem of Rare Disease Screening
Rare diseases affect over 300 million people worldwide. Individually, each condition is uncommon, but together they represent a major global health burden. Advances in genomics have made it technically possible to detect disease-causing variants early even before symptoms appear.
Cell-free DNA (cfDNA) is especially promising. It allows minimally invasive, repeatable testing from blood, making it ideal for carrier screening, early diagnosis, and population scale studies. Yet despite this promise, rare disease screening struggles to scale. The problem isn't access to DNA; it's how current assays are designed.
Why Rare Variant Detection is Fundamentally Hard
Rare disease mutations are, by definition, extremely uncommon. Many occur in fewer than 1 in 10,000 people, and some are unique to a single family. This means the true biological signal is rare to begin with.
In cfDNA, the challenge is even greater. True variants may appear at less than 0.1% frequency, mixed with large amounts of background DNA. At this level, sequencing and PCR errors can look almost identical to real signals. Finding a rare variant once is hard; finding it reliably across thousands of samples is where most approaches fail.
Why Traditional Screening Breaks at Scale
Most genetic screening follows a simple model: one sample, one test. This works for common diseases and small cohorts, but it breaks down for rare disease screening.
Rare disease panels span many genes, and detecting low-frequency variants, especially in cfDNA, requires deep sequencing. Doing this separately for every individual quickly becomes expensive.
Most importantly, rare disease screening demands confidence. A negative result must be as trustworthy as a positive one. With low signal levels and little margin for error, simply running more individual tests is not the answer.
How AlgoBio Solves This
Instead of testing samples one by one, multiple samples are combined into carefully designed pools. Each sample appears in several pools, in a unique pattern. When a real rare variant is present, it repeats across the same set of pools.
This shifts detection from chasing weak signals to recognizing consistent patterns. True variants reinforce themselves, while noise is naturally filtered out without relying on technical replicates.
Pooling also makes deep sequencing affordable. Fewer sequencing reactions are needed, costs drop, and sensitivity is preserved. As more samples are added, the number of pools grows slowly, enabling hundreds or thousands of samples to be screened together.
Most importantly, this structure builds trust. Positive calls are stronger, false signals are reduced, and no variant detected truly means no variant detected.
Conclusion
Rare diseases are common in aggregate, but rare at the molecular level. Screening them at scale requires an approach designed specifically for such rarity. By combining non-invasive cfDNA sampling with multiplex, algorithm-driven pooling and reliable decoding of low-frequency variants, AlgoBio enables rare disease screening to move from individual testing to confident, population-scale detection.